Knight Therapeutics Company Profile (TSE:GUD)

About Knight Therapeutics (TSE:GUD)

Knight Therapeutics logoKnight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: TSE:GUD
  • CUSIP: N/A
  • Web:
  • Market Cap: C$1.23 billion
  • Outstanding Shares: 142,765,000
Average Prices:
  • 50 Day Moving Avg: C$8.63
  • 200 Day Moving Avg: C$9.77
  • 52 Week Range: C$8.25 - C$11.03
  • Trailing P/E Ratio: 60.07
  • P/E Growth: 2880.00
Sales & Book Value:
  • Annual Revenue: C$7.97 million
  • Price / Sales: 154.59
  • Book Value: C$6.87 per share
  • Price / Book: 1.26
  • EBIDTA: ($7,640,000.00)
  • Net Margins: 18.51%
  • Return on Equity: 0.19%
  • Return on Assets: 0.19%
  • Average Volume: 169,151 shs.
  • Short Ratio: 4.2

Frequently Asked Questions for Knight Therapeutics (TSE:GUD)

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Tornton Stock Exchange (TSX) under the ticker symbol "GUD."

How were Knight Therapeutics' earnings last quarter?

Knight Therapeutics Inc (TSE:GUD) posted its quarterly earnings data on Thursday, August, 14th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.02. The company earned $0.25 million during the quarter, compared to analyst estimates of $0.13 million. Knight Therapeutics had a return on equity of 0.19% and a net margin of 18.51%. View Knight Therapeutics' Earnings History.

When will Knight Therapeutics make its next earnings announcement?

Knight Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Knight Therapeutics.

Where is Knight Therapeutics' stock going? Where will Knight Therapeutics' stock price be in 2017?

4 brokers have issued twelve-month price objectives for Knight Therapeutics' shares. Their predictions range from C$9.80 to C$12.50. On average, they expect Knight Therapeutics' stock price to reach C$10.86 in the next year. View Analyst Ratings for Knight Therapeutics.

Who are some of Knight Therapeutics' key competitors?

How do I buy Knight Therapeutics stock?

Shares of Knight Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Knight Therapeutics' stock price today?

One share of Knight Therapeutics stock can currently be purchased for approximately C$8.63.

MarketBeat Community Rating for Knight Therapeutics (TSE GUD)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  70 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  124
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Knight Therapeutics (TSE:GUD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: C$10.86

Analysts' Ratings History for Knight Therapeutics (TSE:GUD)
DateFirmActionRatingPrice TargetDetails
8/11/2017National Bank FinancialLower Price TargetC$11.75 -> C$10.75View Rating Details
5/12/2017ScotiabankLower Price TargetOutperformC$11.00 -> C$10.50View Rating Details
3/20/2017TD SecuritiesReiterated RatingBuyC$12.50View Rating Details
1/13/2017CIBCLower Price TargetC$13.00 -> C$9.80View Rating Details
1/4/2017MackieDowngradeBuy -> HoldC$12.00 -> C$10.75View Rating Details
11/10/2016Bloom BurtonReiterated RatingAccumulateView Rating Details
3/10/2016Paradigm CapitalSet Price TargetBuyC$9.00View Rating Details
3/2/2016Dundee SecuritiesReiterated RatingNeutralView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Knight Therapeutics (TSE:GUD)
Earnings by Quarter for Knight Therapeutics (TSE:GUD)
Earnings History by Quarter for Knight Therapeutics (TSE GUD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2014C($0.01)C$0.01C$0.13 millionC$0.25 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Knight Therapeutics (TSE:GUD)
2017 EPS Consensus Estimate: $0.16
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.04$0.07$0.06
Q2 20171$0.06$0.06$0.06
Q3 20171$0.02$0.02$0.02
Q4 20171$0.02$0.02$0.02
(Data provided by Zacks Investment Research)


Dividend History for Knight Therapeutics (TSE:GUD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Knight Therapeutics (TSE:GUD)
Insider Trades by Quarter for Knight Therapeutics (TSE:GUD)
Insider Trades by Quarter for Knight Therapeutics (TSE:GUD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2015Robert Nathaniel LandeDirectorSell57,000C$8.85C$504,267.60
(Data available from 1/1/2013 forward)


Headline Trends for Knight Therapeutics (TSE:GUD)
Latest Headlines for Knight Therapeutics (TSE:GUD)
DateHeadline logoETFs with exposure to Knight Therapeutics, Inc. : August 16, 2017 - August 16 at 7:19 PM logoKnight Therapeutics, Inc. :GUD-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017 - August 15 at 7:54 PM logoKnight Therapeutics Inc to Post FY2017 Earnings of $0.15 Per Share, National Bank Financial Forecasts (GUD) - August 14 at 4:44 AM logoQ3 2017 Earnings Estimate for Knight Therapeutics Inc (TSE:GUD) Issued By Cormark - August 14 at 1:40 AM logoKnight Therapeutics Inc (TSE:GUD) Price Target Lowered to C$10.75 at National Bank Financial - August 11 at 10:22 PM logoKnight Reports Second Quarter 2017 Results - August 11 at 1:26 AM logoSynergy CHC Corp. Secures up to US$30 Million of Growth Capital - August 11 at 1:26 AM logoEdited Transcript of GUD.TO earnings conference call or presentation 10-Aug-17 12:30pm GMT - August 11 at 1:26 AM logoKnight Supports Synergy with Third Secured Loan - August 9 at 7:28 PM logoKnight Therapeutics Inc (GUD) to Release Quarterly Earnings on Thursday - August 4 at 3:32 PM logoNotice of Knight Therapeutics' Second Quarter 2017 Results Conference Call - August 3 at 7:19 PM logoKnight Therapeutics, Inc. :GUD-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017 - August 3 at 7:19 PM logoETFs with exposure to Knight Therapeutics, Inc. : July 24, 2017 - July 24 at 9:44 PM logoETFs with exposure to Knight Therapeutics, Inc. : July 14, 2017 - July 14 at 8:26 PM logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : July 7, 2017 - July 8 at 11:16 AM logoCanadian Healthcare Stocks Under Review: Valeant Pharma International, Knight Therapeutics, Merus Labs International, and Nuvo Pharma - June 30 at 7:29 PM logoKnight Therapeutics, Inc. – Value Analysis (TORONTO:GUD) : June 26, 2017 - June 26 at 7:17 PM logoKnight to Present at the Jefferies Global Healthcare Conference in New York City - June 2 at 6:54 PM logoKnight to Present at the National Bank Financial Quebec Conference in Toronto - May 31 at 8:51 AM logoKnight Therapeutics Inc to Post FY2017 Earnings of $0.19 Per Share, National Bank Financial Forecasts (GUD) - May 15 at 8:30 AM logoQ1 2017 EPS Estimates for Knight Therapeutics Inc Increased by Cormark (GUD) - May 15 at 7:00 AM logoKnight Therapeutics Inc (GUD) Receives Average Rating of "Buy" from Analysts - May 12 at 9:14 PM logoScotiabank Lowers Knight Therapeutics Inc (GUD) Price Target to C$10.50 - May 12 at 7:41 PM logoAnalysts Offer Predictions for Knight Therapeutics Inc's Q1 2017 Earnings (GUD) - May 12 at 6:20 PM logoKnight Therapeutics Inc Expected to Post Q2 2017 Earnings of $0.06 Per Share (GUD) - May 12 at 6:20 PM logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : GUD-CA : May 12, 2017 - May 12 at 6:14 PM logo‘Purge’ killer given 3 life sentences - May 11 at 11:10 PM logoTrump Administration Announces Deal With China to Boost Exports - May 11 at 11:10 PM logoNo charges for white officer in Nashville who shot and killed black man - May 11 at 11:10 PM logoHanford Nuclear Site’s Collapsed Tunnel May Have Gone Unnoticed - May 11 at 11:10 PM logoKnight Reports First Quarter 2017 Results - May 11 at 6:09 PM logoWhat to Expect for Summer Travel - May 10 at 12:20 PM logoIraqi boys recount horrors of captivity by IS - May 10 at 12:20 PM logoCarney Told to Be Ruthless in Pushing Through BOE Overhaul - May 10 at 12:20 PM logoCitigroup Trader Fired Over 5-Word Message Uses 2-Second Defense - May 10 at 12:20 PM logoDonald Trump Says He Fired FBI Director Because He Wasn't 'Doing A Good Job' - May 10 at 12:20 PM logoKnight Therapeutics Inc. announces voting results from the Annual Meeting - May 10 at 12:20 PM logo82nd Airborne already on way to Afghanistan as Trump mulls more deployments - May 9 at 5:23 PM logoWhite House Skeptical of Yates’ Heads Up on Flynn, Cited Partisan Motives - May 9 at 5:23 PM logoGOP senators can cut Obamacare taxes or preserve coverage for millions — but probably not both - May 9 at 5:23 PM logoAudio Reveals Final Pleas Of Hundreds Of Refugees Trapped On A Sinking Boat - May 9 at 12:43 PM logoMeghan Markle, Prince Harry show PDA at polo match for first time - May 8 at 8:20 AM logo2 doctors found dead in Boston penthouse probably knew their killer, police say - May 7 at 10:49 PM logoWhat's at stake as Trump gets to 'see you in court' in two major travel ban cases - May 7 at 10:49 PM logoAli Lowitzer’s Mother Pushes for Day Daughter Disappeared to Become Texas Missing Persons Day - May 7 at 10:49 PM logoTexas governor signs bill targeting sanctuary cities - May 7 at 10:49 PM logoNicki Minaj Offers to Pay Over a Dozen Fans’ Student Loans on Twitter - May 7 at 5:49 PM logoNorth Korea Detains Fourth American Citizen: KCNA Report - May 7 at 10:01 AM logoAunt Jemima Products Recalled Due to Possible Listeria Contamination - May 6 at 5:40 PM logoObama White House counsel part of early talks on Clinton email release, notes show - May 5 at 9:11 PM



Knight Therapeutics (GUD) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff